Form 4: Amylyx Pharmaceuticals Co-CEO Justin B. Klee Sells Shares to Cover Tax Obligations

Justin B. Klee, Co-CEO of Amylyx Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On September 30, 2024, Justin B. Klee, Co-CEO of Amylyx Pharmaceuticals, sold 18,589 shares of common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $3.197, with individual transactions ranging from $3.145 to $3.245.
• Following the transaction, Klee directly owns 3,120,569 shares of Amylyx Pharmaceuticals.
• The sale was automatic and not at the discretion of the reporting person.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale for tax obligations) by a company executive. It doesn't inherently indicate positive or negative sentiment regarding the company's performance or future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This sale appears to be related to tax obligations, which is a common occurrence.

Stakeholder Impact

• The sale of shares by a company executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact as it was to cover tax obligations.

Key Dates